Concord Biotech Balance Sheet Health
Financial Health criteria checks 6/6
Concord Biotech has a total shareholder equity of ₹15.9B and total debt of ₹0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₹17.6B and ₹1.7B respectively. Concord Biotech's EBIT is ₹4.1B making its interest coverage ratio -236.6. It has cash and short-term investments of ₹2.8B.
Key information
0%
Debt to equity ratio
₹0
Debt
| Interest coverage ratio | -236.6x |
| Cash | ₹2.84b |
| Equity | ₹15.90b |
| Total liabilities | ₹1.74b |
| Total assets | ₹17.64b |
Recent financial health updates
Recent updates
Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Nov 14
Do Concord Biotech's (NSE:CONCORDBIO) Earnings Warrant Your Attention?
Sep 15Concord Biotech Limited (NSE:CONCORDBIO) Not Lagging Market On Growth Or Pricing
Jul 23Is Concord Biotech (NSE:CONCORDBIO) Using Too Much Debt?
Feb 14Financial Position Analysis
Short Term Liabilities: CONCORDBIO's short term assets (₹9.3B) exceed its short term liabilities (₹1.4B).
Long Term Liabilities: CONCORDBIO's short term assets (₹9.3B) exceed its long term liabilities (₹322.5M).
Debt to Equity History and Analysis
Debt Level: CONCORDBIO is debt free.
Reducing Debt: CONCORDBIO had no debt 5 years ago.
Debt Coverage: CONCORDBIO has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CONCORDBIO has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 06:51 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Concord Biotech Limited is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Antique Stockbroking Ltd. |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |
| Deepika Murarka | Choice Equity Broking Private Limited |